Dissolution enhancement of glibenclamide by solid dispersion: Solvent evaporation versus a supercritical fluid-based solvent -antisolvent technique

Research in Pharmaceutical Sciences

Volumn 9, Issue 5, 2014, Pages 337-350

  Tabbakhian, M ^a   Hasanzadeh, F ^a   Tavakoli, N ^a   Jamshidian, Z ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dissolution enhancement; Glibenclamide; Solid dispersion; Solvent evaporation; Supercritical fluid

Indexed keywords

CARBON DIOXIDE; DRUG CARRIER; GLIBENCLAMIDE; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL 6000; PLASTICIZER; POLOXAMER; POLYMER; SOLVENT;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DILUTION; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; EVAPORATION; INFRARED SPECTROSCOPY; INTERMETHOD COMPARISON; SOLID DISPERSION FORMULATION; SOLVENT EFFECT; SOLVENT EVAPORATION; SUPERCRITICAL FLUID; SUPERCRITICAL FLUID SOLVENT ANTISOLVENT TECHNIQUE; X RAY POWDER DIFFRACTION;

EID: 84897145485     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068-1075. (Pubitemid 350186132)
2. Patel SG, Rajput SJ. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS Pharm Sci Tech. 2009;10:660-669.
3. Won DH, Kim MS, Lee S, Park JS, Hwang SJ. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm. 2005;301:199-208. (Pubitemid 41206604)
4. Vemavarapu C, Mollan MJ, Lodaya M, Needham TE. Design and process aspects of laboratory scale SCF particle formation systems. Int J Pharm. 2005;292:1-16. (Pubitemid 40255784)
5. Davies OR, Lewis AL, Whitaker MJ, Tai H, Shakesheff KM, Howdle SM. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv Drug Deliv Rev. 2008;60:373-387.
6. Thote AJ, Gupta RB. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Dis Month. 2005;51:362-373.
7. Pasquali I, Bettini R. Are pharmaceutics really going supercritical? Int J Pharm. 2008;364:176-187.
8. Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev. 2008;60:399-410. (Pubitemid 351217081)
9. Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. Cur Opin Solid StM. 2003;7:371-383. (Pubitemid 38462044)
10. Duarte AR, Roy C, Vega-González A, Duarte CMM, Subra-Paternault P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm. 2007;332:132-139. (Pubitemid 46227780)
11. Sui X, Wei W, Yang L, Zu Y, Zhao C, Zhang L, et al. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. Int J Pharm. 2012;423:471-479.
12. Lobenberg R, Kramer J, Shah VP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res. 2000;17:439-444. (Pubitemid 30395299)
13. Wei H, Dalton C, Maso M, Kanfer I, Lobenberg R. Physicochemical characterization of five glyburide powders: A BCS-based approach to predict oral absorption. Eur J Pharm Biopharm. 2008;69:1046-1056.
14. Wei H, Lobenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci. 2006;29:45-52. (Pubitemid 44279396)
15. Krgel I, Bodmeier R. Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder. J Control Release. 1999;61:43-50. (Pubitemid 29406078)
16. Bertram U, Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form. Eur J Pharm Sci. 2006;27:62-71. (Pubitemid 41728256)
17. Leonardi Do, Barrera Ma, Lamas Ma, Salomn C. Development of prednisone: Polyethylene glycol 6000 fast-release tablets from solid dispersions: Solid-state characterization, dissolution behavior, and formulation parameters. AAPS Pharm Sci Tech. 2007;8:221-228.
18. Dumortier G, Grossiord J, Agnely F, Chaumeil J. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709-2728. (Pubitemid 44885361)
19. Newa M, Bhandari K, Oh D, Kim Y, Sung J, Kim J, et al. Enhanced dissolution of ibuprofen using solid dispersion with poloxamer 407. Arch Pharm Res. 2008;31:1497-1507.
20. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci. 2000;10:43-52. (Pubitemid 30123143)
21. Mura P, Furlanetto S, Cirri M, Maestrelli F, Marras AM, Pinzauti S. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. J Pharm Biomed Anal. 2005;37:65-71. (Pubitemid 40138717)
22. United States Pharmacopeial Convention. USP 31. United States Pharmacopeial Convention; 2007.
23. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. European J Pharm Sci. 2001;13:123-133. . (Pubitemid 32288781)
24. Wei H, Dalton C, Maso M, Kanfer I, Löbenberg R. Physicochemical characterization of five glyburide powders: A BCS-based approach to predict oral absorption. Eur J Pharm Biopharm. 2008;69:1046-1056.
25. Shah T, Amin A, Parikh J, Parikh R. Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. AAPS Pharm Sci Tech. 2007;8:E18-E24.
26. Bartsch SE, Griesser UJ. Physicochemical properties of the binary system glibenclamide and polyethylene glycol 4000. J Therm Anal Calorim. 2004;77:555-569.
27. Rehder S, Sakmann A, Rades T, Leopold CS. Thermal degradation of amorphous glibenclamide. Eur J Pharm Biopharm. 2012;80:203-208.
28. Janssens S, de Armas HN, Roberts CJ, Van den Mooter G. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci. 2008;97:2110-2220.
29. Ugaonkar S, Nunes AC, Needham TE. Effect of nscCO2 on crystalline to amorphous conversion of carbamazepine. Int J Pharm. 2007;333:152-161. (Pubitemid 46283281)
30. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47-60. (Pubitemid 30326688)
31. Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int J Pharm. 2001;222:139-151. (Pubitemid 32525795)
32. Rodier E, Lochard H, Sauceau M, Letourneau JJ, Freiss B, Fages J. A three step supercritical process to improve the dissolution rate of Eflucimibe. Eur J Pharm Sci. 2005;26:184-193. (Pubitemid 41169801)